Grace Halsey

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.

Pain relief with suzetrigine was comparable to that seen with placebo, an issue Vertex plans to address with study design as the drug moves to the pivotal phase 3 trials.

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.

The addition, based on an approved update to labeling, expands to 4 the recommended vaccination options that health care professionals can offer to pregnant people.

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.

The National Foundation for Infectious Diseases medical director appeals to the community at large to set politics and personal grievance aside and to "first, do no harm."

From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.

If approved, the nonopioid, centrally acting analgesic would be the first in a new class of medications for fibromyalgia in more than 15 years, Tonix said.

The lead investigator of the largest clinical trial program in people with CAH discusses the condition, its burden, and the novel drug just approved that will change lives.

Clesrovimab, if approved, would be the only immunization for both healthy and at risk infants using the same dose. FDA set A PDUFA date of June 2025.

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

Approval for the topical nonsteroidal therapy, based on data from the phase 3 ADORING clinical trial program, helps fill a gap in current offerings for atopic dermatitis.

Auchus details findings from the unique study of the CRF-1 antagonist crinecerfont, the first new therapy for CAH approved in 70 years.

Crinecerfont approval makes available the first new treatment for the life-altering endocrine disorder in more than 70 years, according to Neurocrine Biosciences.

Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.

The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

Hopkins, of the National Foundation for Infectious Diseases, is frustrated by the diminished societal response to the virus' circulation including ongoing low vaccination rates.

Moderna paused clinical research on the pediatric shot indefinitely in September after reports in July of severe adverse reactions in infants aged 5 to 8 months.

An analysis of patient reported outcome measures from 3 pivotal phase 3 RCTs of atogepant 60 mg demonstrates efficacy across functional domains as well as for migraine prevention.

An MDF stethoscope with leopard print tubing? A digital highlighter/scanner that translates and talks back? Check out these and 8 more uncommon gifts for health care professionals.

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

Americans' rating of the quality of health care available in the US has hit its lowest in 24 years, according to a new Gallup survey; here's what they think.

Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.

How does alcohol figure in to American holiday celebrations? We checked with Alcohol.org for this quiz. Are answers what you expect?

Dupilumab significantly reduced signs and symptoms of AD in children aged 6 months to 5 years with concomitant asthma, allergic rhinitis, and food allergy.

The CGRP inhibitor fremanezumab reduced both monthly migraine and monthly headache days among children aged 6 to 17 years with a favorable safety profile.

"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.